ディスク・メディシン
Disc Medicine, Inc.
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -1.65 | $0 | -$62M |
| 2025 Q4 | -1.64 | $0 | -$43M |
| 2025 Q3 | -1.77 | $0 | -$48M |
| 2025 Q2 | -1.58 | $0 | -$48M |
| 2025 Q1 | -1.02 | $0 | -$42M |
| 2024 Q4 | -0.98 | $0 | -$28M |
| 2024 Q3 |
| -0.89 |
| $0 |
| -$17M |
| 2024 Q2 | -1.03 | $0 | -$15M |